November 2021, Vol 11, No 11

The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning. According to research presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium, pairing a highly trained nurse practitioner with a primary care team to engage patients in this process can lead to better healthcare utilization and higher quality end-of-life care. Read More ›

A single dose of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen–directed CAR T-cell therapy, resulted in early, deep, and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma, according to updated results from the phase 1b/2 CARTITUDE-1 clinical trial. These findings were reported by Saad Zafar Usmani, MD, FACP, Director, Plasma Cell Disorder Program, and Director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Charlotte, NC, at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

Adoption of biosimilars continues to rise in the United States, but oncologists’ knowledge regarding these agents has not kept pace, according to data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium. Read More ›

The development of biosimilar medicines has provided an opportunity for patient utilization of oncology treatments at a lower cost, particularly in individuals for whom biologicals play a predominant role in providing effective therapeutic and supportive care. Although there has been an increase in the use of biosimilars in recent years, challenges to mass adoption remain. According to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium, however, utilization of the biosimilar trastuzumab-anns (Kanjinti) is trending in the right direction. Read More ›

On August 20, 2021, a group of 16 organizations representing patients, consumers, providers, and taxpayers published an open letter to officials from the Centers for Medicare & Medicaid Services and the Department of Health and Human Services asking them to consider enacting a zero copay policy for Medicare Part B patients, a move the groups said would improve access to biosimilars and save seniors in Medicare as much as $3 billion in out-of-pocket costs. Read More ›

Dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with EGFR-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial, presented at the American Society of Clinical Oncology 2021 virtual annual meeting. The study also provided insights into resistance mechanisms in patients previously treated with osimertinib. Read More ›

Clinical trials are critical for evaluating novel therapies and determining the best treatment strategies to enhance outcomes for patients with cancer. However, most clinical trials do not meet their enrollment targets due to both structural and clinical barriers. Studies have shown that 85% of patients receive their treatment in a community setting, resulting in up to 55.6% not participating in clinical trials because there are none available, while an additional 21.5% are eliminated due to eligibility criteria. To further compound the situation, clinical trial activities have been adversely affected by the COVID-19 pandemic. Read More ›

Preliminary results from the first prospective study of a genomic classifier for African-American men suggest that both disparities in access to care and biological factors may be responsible for the increased incidence and mortality in this patient population. The study also identified a significant age difference between African-American and non–African-American men with respect to high genomic risk. These findings were presented during the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

Early results from the CheckMate-648 clinical trial, which evaluated the 1 and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, sugge1st a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC). These findings were presented at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting by Ian Chau, MD, Consultant Medical Oncologist, Gastrointestinal and Haemato-Oncology, Royal Marsden Hospital, Sutton, United Kingdom, and lead investigator of the trial. Read More ›

I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA. Read More ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: